Rhumbline Advisers Denali Therapeutics Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 171,959 shares of DNLI stock, worth $3.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,959

Previous 166,763 3.12%

Holding current value

$3.74 Million

Previous $3.58 Million 1.4%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$15.83 - $23.35 $82,252 - $121,326	5,196 Added 3.12%	171,959 $3.53 Million
Q4 2023 Feb 08, 2024	SELL	$16.2 - $23.18 $38,248 - $54,727	-2,361 Reduced 1.4%	166,763 $3.58 Million
Q3 2023 Nov 09, 2023	BUY	$20.63 - $30.17 $147,339 - $215,474	7,142 Added 4.41%	169,124 $3.49 Million
Q2 2023 Aug 08, 2023	BUY	$23.37 - $32.96 $370,180 - $522,086	15,840 Added 10.84%	161,982 $4.78 Million
Q1 2023 May 11, 2023	BUY	$21.91 - $32.67 $70,331 - $104,870	3,210 Added 2.25%	146,142 $3.37 Million

Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $394,173 - $508,766	14,999 Added 11.72%	142,932 $3.98 Million
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $271,594 - $402,946	10,458 Added 8.9%	127,933 $3.93 Million
Q2 2022 Aug 11, 2022	BUY	$20.88 - $35.19 $424,490 - $715,412	20,330 Added 20.93%	117,475 $3.46 Million
Q1 2022 May 12, 2022	BUY	$29.0 - $47.27 $14,384 - $23,445	496 Added 0.51%	97,145 $3.13 Million
Q4 2021 Feb 10, 2022	SELL	$42.59 - $55.02 $32,198 - $41,595	-756 Reduced 0.78%	96,649 $4.31 Million
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $123,623 - $199,486	2,550 Added 2.69%	97,405 $4.91 Million
Q2 2021 Aug 05, 2021	BUY	$50.3 - $78.44 $1.17 Million - $1.83 Million	23,280 Added 32.53%	94,855 $7.44 Million
Q1 2021 May 06, 2021	SELL	$53.8 - $81.53 $432,982 - $656,153	-8,048 Reduced 10.11%	71,575 $4.09 Million
Q4 2020 Feb 10, 2021	BUY	$36.89 - $93.56 $19,477 - $49,399	528 Added 0.67%	79,623 $6.67 Million
Q3 2020 Nov 12, 2020	SELL	$23.13 - $38.84 $273,396 - $459,088	-11,820 Reduced 13.0%	79,095 $2.83 Million
Q2 2020 Aug 13, 2020	BUY	$16.01 - $28.82 $400,009 - $720,067	24,985 Added 37.9%	90,915 $2.2 Million
Q1 2020 May 06, 2020	BUY	$14.2 - $27.98 $34,335 - $67,655	2,418 Added 3.81%	65,930 $1.15 Million
Q4 2019 Feb 05, 2020	BUY	$14.4 - $19.99 $11,260 - $15,632	782 Added 1.25%	63,512 $1.11 Million
Q3 2019 Oct 23, 2019	SELL	$15.32 - $21.92 $10,065 - $14,401	-657 Reduced 1.04%	62,730 $961,000
Q2 2019 Aug 14, 2019	BUY	$18.5 - $28.14 $59,274 - $90,160	3,204 Added 5.32%	63,387 $1.32 Million
Q1 2019 May 01, 2019	SELL	$17.99 - $24.65 $11,981 - $16,416	-666 Reduced 1.09%	60,183 $1.4 Million
Q4 2018 Jan 31, 2019	BUY	$13.88 - $21.75 $315,242 - $493,986	22,712 Added 59.55%	60,849 $1.26 Million
Q3 2018 Nov 07, 2018	BUY	$12.46 - $21.74 $273,197 - $476,671	21,926 Added 135.25%	38,137 $829,000
Q2 2018 Aug 06, 2018	BUY	$15.25 - $21.02 $35,166 - $48,472	2,306 Added 16.58%	16,211 $247,000
Q1 2018 May 02, 2018	BUY	$15.36 - $24.8 $213,580 - $344,844	13,905 New	13,905 $274,000

Others Institutions Holding DNLI

# of Institutions

217

Shares Held

115M

Call Options Held

142K

Put Options Held

90.3K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.92B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Denali Therapeutics Inc. Transaction History